An antibody drug conjugate targeting a GSTA glycosite-signature epitope of mucin1 expressed by non-small cell lung cancer
Preprint
- 30 December 2019
- preprint
- Published by Cold Spring Harbor Laboratory in bioRxiv
Abstract
Background: Antibodies targeting abnormally glycosylated proteins have been ineffective in treating cancer. Antibody-drug conjugates are emerging as an efficient option, which allow specific delivery of drugs into tumors. We and others have dissected the abnormally glycosylated tandem repeat region of MUC1 glycoprotein as three site-specific glycosylated neoantigen peptide motifs (PDTR, GSTA, GVTS) for monoclonal antibody binding.Methods: Internalization of monoclonal antibodies was studied by immunofluorescence staining and colocalization with lysosomal markers in live cells. Antibody positivity in tumor and peritumoral tissue samples were studied by immunohistochemistry. The efficacy of anti-MUC1 ADCs were evaluated with various cancer cell lines and mouse tumor xenograft model.Results: We describe an anti-MUC1 ADC by conjugating GSTA neoantigen-specific 16A with monomethyl auristatin E (MMAE). 16A-MMAE showed potent antitumoral efficacy with IC50ranging from 0.2 to 49.4 nM toward multiple types of cancer cells.In vivo, 16A-MMAE showed dose-dependent inhibition of tumor growth in mouse xenograft of NCI-H838 NSCLC cell line, with minimum effective dose at 1 mg/kg. At the dose of 3 mg/kg, 16A-MMAE did not cause significant toxicity in a transgenic mouse expressing human MUC1.Conclusions: The high antitumoral efficacy of 16A-MMAE suggest that aberrant glycosylated MUC1 neoantigen is a target with high positivity in multiple cancer types for ADC development. Personalized therapy may be achieved by development of glycosite-specific antibody-drug conjugates.Keywords
All Related Versions
- Published version: Cancer Medicine, 9 (24), 9529.
This publication has 36 references indexed in Scilit:
- Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided TherapyMolecules, 2018
- A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomasEuropean Journal of Cancer, 2016
- Autoantibodies against the signal peptide domain of MUC1 in patients with multiple myeloma: Implications for disease diagnosis and prognosisExperimental and Therapeutic Medicine, 2012
- Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast CancerClinical Cancer Research, 2011
- High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC)Cancer Letters, 2007
- Glycopeptides as versatile tools for glycobiologyGlycobiology, 2006
- Significance of MUC1 and MUC2 mucin expression in colorectal cancer.Journal of Clinical Pathology, 1996
- Prognostic significance of muc1 epithelial mucin expression in breast cancer*1Human Pathology, 1995
- The mouse episialin (Muc1) gene and its promoter: Rapid evolution of the repetitive domain in the proteinBiochemical and Biophysical Research Communications, 1991
- Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unitBiochemical and Biophysical Research Communications, 1990